Data Insights

Zolbetuximab by Astellas Pharma for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Zolbetuximab is under clinical development by Astellas Pharma and currently in Pre-Registration for Adenocarcinoma Of The Gastroesophageal Junction. According to...

Data Insights

Zolbetuximab by Astellas Pharma for Gastric Cancer: Likelihood of Approval

Zolbetuximab is under clinical development by Astellas Pharma and currently in Pre-Registration for Gastric Cancer. According to GlobalData, Pre-Registration drugs...

Data Insights

ASP-3082 by Astellas Pharma for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Data Insights

ASP-3082 by Astellas Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval

ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Data Insights

ASP-3082 by Astellas Pharma for Colorectal Cancer: Likelihood of Approval

ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...

Data Insights

ASP-3082 by Astellas Pharma for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - ASP-3082 in Pancreatic Ductal Adenocarcinoma

Data Insights

Enfortumab vedotin by Astellas Pharma for Peritoneal Cancer: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase I for Peritoneal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Peritoneal Cancer

Data Insights

Enfortumab vedotin by Astellas Pharma for Fallopian Tube Cancer: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase I for Fallopian Tube Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Fallopian Tube Cancer

Data Insights

Enfortumab vedotin by Astellas Pharma for Epithelial Ovarian Cancer: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase I for Epithelial Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Epithelial Ovarian Cancer

Data Insights

Mirabegron ER by Astellas Pharma for Esophageal Achalasia: Likelihood of Approval

Mirabegron ER is under clinical development by Astellas Pharma and currently in Phase I for Esophageal Achalasia. According to GlobalData,...

Data Insights

ASP-7317 by Astellas Pharma for Juvenile Macular Degeneration (Stargardt Disease): Likelihood of Approval

ASP-7317 is under clinical development by Astellas Pharma and currently in Phase II for Juvenile Macular Degeneration (Stargardt Disease). According...

Likelihood of Approval and Phase Transition Success Rate Model - ASP-7317 in Juvenile Macular Degeneration (Stargardt Disease)

Data Insights

Ramosetron by Astellas Pharma for Fecal Incontinence: Likelihood of Approval

Ramosetron is under clinical development by Astellas Pharma and currently in Phase III for Fecal Incontinence. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ramosetron in Fecal Incontinence

Data Insights

ASP-2802 by Astellas Pharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - ASP-2802 in Diffuse Large B-Cell Lymphoma

Data Insights

ASP-2802 by Astellas Pharma for T-Cell Lymphomas: Likelihood of Approval

ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - ASP-2802 in T-Cell Lymphomas

Data Insights

ASP-2802 by Astellas Pharma for Follicular Lymphoma: Likelihood of Approval

ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - ASP-2802 in Follicular Lymphoma

Data Insights

ASP-2802 by Astellas Pharma for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - ASP-2802 in Primary Mediastinal B-Cell Lymphoma

Data Insights

ASP-2802 by Astellas Pharma for Marginal Zone B-cell Lymphoma: Likelihood of Approval

ASP-2802 is under clinical development by Astellas Pharma and currently in Phase I for Marginal Zone B-cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - ASP-2802 in Marginal Zone B-cell Lymphoma

Data Insights

Enfortumab vedotin by Astellas Pharma for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Enfortumab vedotin by Astellas Pharma for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase III for Transitional Cell Carcinoma (Urothelial Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

ASP-7317 by Astellas Pharma for Dry (Atrophic) Macular Degeneration: Likelihood of Approval

ASP-7317 is under clinical development by Astellas Pharma and currently in Phase II for Dry (Atrophic) Macular Degeneration. According to...

Likelihood of Approval and Phase Transition Success Rate Model - ASP-7317 in Dry (Atrophic) Macular Degeneration